04 · Alert System
Recalls, enforcement actions, and viral ingredient spikes requiring immediate consultant awareness. Red requires action, amber requires monitoring, green flags opportunity.
Last reviewed May 2026
2 red alerts activeMultiple brands using explicit GLP-1 equivalence language in marketing. FTC updated Health Products Compliance Guidance (Dec 2022) applies directly — unsubstantiated disease claims are actionable. Clinical reality: berberine produces 2–4kg weight loss vs 10%+ for prescription GLP-1 drugs. Enforcement action likely in 2026. Brand clients should audit all marketing copy immediately and migrate to defensible structure/function claims: blood sugar support, metabolic health, insulin sensitivity.
Consumer search and social signals also inform velocity rating.
Searches up 309% YoY driven by Bryan Johnson and RFK Jr. association. Methylene blue is NOT approved as a dietary supplement in the US, EU, or UK — it is an FDA-approved drug for methemoglobinemia only. Industrial and aquarium grades sold online may contain arsenic, lead, and aluminium residues. Serotonin syndrome risk is serious and potentially life-threatening for patients on SSRIs or other antidepressants (Zoloft, Lexapro). Monitor for FDA warning letters to online retailers and watch for enforcement escalation.
Consumer search and social signals also inform velocity rating.
Consumer search and social signals also inform velocity rating.
NMN remains under novel food assessment in the EU. UK FSA is monitoring. NutraIngredients (Feb 2026) reports EU/UK regulators actively flagging "anti-aging," "cellular repair," and "extends lifespan" language as unauthorised health claims. US market is clear following FDA 2025 reinstatement. European-facing brands should audit claim language immediately.
Council for Responsible Nutrition filed formal proposal March 2026 to reform drug preclusion rules. Affects NMN, NR, and other ingredients previously investigated as drug candidates. If successful, removes regulatory overhang on a category of longevity ingredients. FDA response expected H2 2026. Watch for public comment period opening.
New peer-reviewed study finds more than one in five turmeric-containing supplements contain synthetic curcumin, undeclared dyes, or diluents. Strengthens the case for USP verification mark, NSF certification, and third-party testing as positioning differentiators for quality-led brands. Use in client quality strategy briefings.
Consumer search and social signals also inform velocity rating.
Vitamin Shoppe reports +40% Q1 sales and +52% searches YTD. Wild-harvested shilajit has documented heavy metal contamination variance (arsenic, lead, mercury). PrimaVie branded extract is the only commercially validated form with consistent specification and clinical data. Generic sourcing is a growing consumer risk as demand outpaces quality infrastructure. Advise clients to specify branded ingredient or conduct independent CoA verification.
FDA's food division head signaled the agency is likely to propose a rule allowing supplement companies to include the required DSHEA disclaimer once per label, rather than adjacent to each individual health claim. No formal rulemaking timeline has been established and current requirements remain unenforced during the review period. FTC is unaffected — substantiation requirements for advertising claims are unchanged. Brands with multiple structure-function claims should begin redesigning label architecture now for the new single-disclaimer standard.
Consumer search and social signals also inform velocity rating.
Nevada-based TruHeight agreed to pay $750,000 to settle FTC charges that it deceptively advertised height-enhancing supplements for children and teenagers, and used employee-written and incentivised reviews. The action confirms FTC is actively pursuing unsubstantiated supplement claims. Industry analysts anticipate increased enforcement activity to counterbalance perceived regulatory softening elsewhere. Berberine GLP-1 claims remain the highest risk category.
Consumer search and social signals also inform velocity rating.
Consumer search and social signals also inform velocity rating.
Multiple industry reports confirm "GLP-1 companion" as a structurally defensible and evidence-backed product sub-category. B-complex, D3/K2, magnesium positioned as nutritional support — not GLP-1 mimics. Claim framework is defensible; evidence base is solid. This is the better market entry point for brands currently tempted by GLP-1 equivalence language. First-mover opportunity remains open for a credibly formulated, transparently labelled companion stack.
Consumer search and social signals also inform velocity rating.
Timeline's Mitopure gummy launch (Mar 2026) confirms postbiotic shelf-stability advantage is commercially validated at premium price point. Removes refrigeration barrier for DTC subscription models — opens new channel economics for gut health and longevity brands. Postbiotics avoid the "dead bacteria" consumer concern with standard probiotics, have demonstrated RCT data (urolithin A, heat-killed Akkermansia), and are viable in any delivery format. Category is accelerating.
"The regulatory and claim environment in dietary supplements has never been more consequential. Getting the evidence framing right is as important as the formulation itself."
Schedule a consultation →